Human glioma U-251 cells contain type 1 plasminogen activator inhibitor in a rapidly releasable form  by Salonen, Eeva-Marjatta et al.
FEBS Letters 393 (1996) 216-220 FEBS 17472 
Human glioma U-251 cells contain type 1 plasminogen activator inhibitor 
in a rapidly releasable form 
Eeva-Marjatta Salonen a,b, Lourdes Gombau% Eva Engvall ~, Raymond R. Schleef ~,* 
~Department of Vascular Biology, The Scripps Research Institute, 10666 N. Torrey Pines Rd., La Jolla, CA 92037, USA 
~Department of Virology, Haartman Institute, University of Helsinki, Finland 
< The Burnham Institute, 10901 N. Torrey Pines Rd.. La Jolla, CA 92037, USA 
Received 16 June 1996; revised version received 24 July 1996 
Abstract Because recent information suggests that the localized 
deposition of protease inhibitors is one mechanism by which cells 
regulate pericellular proteolysis during tissue invasion, the 
distribution of type 1 plasminogen activator inhibitor (PAl- l) 
associated with the invasive human glioma cell line U-251 was 
investigated. Direct and reverse fibrin zymography indicated the 
presence of urokinase-like plasminogen activator (u-PA) and 
PAI-1 in U-251 conditioned media and cell lysates. PAI-I 
antigen was detected immunologically in cytoplasmic granules 
present within cellular processes of U-251 cells and these 
organelles could be isolated on Percoll density gradients in a 
high density band. In contrast, u-PA activity and another 
secreted protein, amyloid [5-protein precursor, were only present 
in the low density region of the gradients. Functional analysis of 
PAI-1 in the granules contained within the high density fractions 
revealed the presence of active PAl-1. Incubation of U-251 cells 
with the secretagogue, 8-bromoadenosine 3' :5'-cyclic monophos- 
phate, resulted in a 3-fold increase in the release of PAI-1 in the 
media conditioned by these cells. These data suggest that the 
human glioma cell line U-251 contains PAI-I in a rapidly 
releasable form, which may provide another mechanism by which 
these tumors could regulate proteolytic activity in a localized 
manner. 
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I. Introduction 
Primary tumors of the central nervous system account for 
approx. 1.2% of all autopsied eaths and 40-50% of intracra- 
nial tumors, with the majority of these tumors being derived 
not from neurons but from the glia (reviews [1 3]). Malignant 
gliomas are classified histologically according to their resem- 
blance to normal cells from the central nervous system, with 
astrocytes and oligodendrocytes being two major groups of 
glia within the central nervous system [1-3]. The poor prog- 
nosis of gliomas is partly mediated by the resistance of these 
tumors to cytostatics and irradiation, and because a total 
tumor resection is often difficult due to diffuse infiltrative 
growth into adjacent brain areas [1 3]. The infiltrative growth 
pattern of gliomas is usually along preformed nerve pathways 
(e.g. corpus callosum), around vessels, or the leptomeninges. 
Because proteolytic enzymes play a key role in modifying the 
extracellular matrix (ECM) during tumor infiltration within 
the human brain (reviews [3 6]), detailed information on the 
mechanisms that regulate protease activities ecreted by glio- 
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mas is essential for an understanding of their infiltrative 
growth pattern. 
Current information suggests that the plasminogen activa- 
tion system plays an important role in the degradation of the 
ECM required for the migration of cells (reviews [3-8]). Plas- 
minogen circulates as a proenzyme at high concentrations in 
the vasculature and is proteolytically converted into an active 
enzyme, plasmin, which is not only capable of degrading ma- 
trix components (e.g. fibronectin and laminin), but also of 
activating latent matrix-degrading enzymes (e.g. procolla- 
genases and macrophage lastase). The activation of the zy- 
mogen plasminogen is primarily mediated by the activity of 
two distinct classes of enzymes (i.e. tissue-type plasminogen 
activator, t-PA; urokinase-like plasminogen activator, u-PA) 
[3 8]. Bindal et al. [4] noted that high levels of u-PA and low 
or absent t-PA activity correlated with histologically malig- 
nant brain tumors, aggressive infiltrative characteristics, and 
shorter patient survival. The ability of u-PA to bind to and be 
localized to a receptor at the leading edge of migrating cells 
has been proposed as one mechanism that cells utilize to di- 
rect the extracellular proteolysis to the cell-cell and cell-sub- 
stratum contacts [8]. In situ analysis has revealed an enhanced 
expression for the u-PA receptor at the leading edge of human 
gliomas [9], and antibodies to the u-PA receptor effectively 
block the invasion of four glioblastoma cell lines (e.g. U-251 
cells) in an in vitro matrigel assay [10]. Immunohistochemical 
localization studies for u-PA antigen have revealed that all 
anaplastic astrocytomas nd glioblastomas contain a prepon- 
derance of neoplastic ells immunoreactive for u-PA [11,12]. 
A series of serine protease inhibitors (serpins) appears to be 
utilized by cells to control the activation of plasminogen, with 
prevailing data suggesting that type 1 plasminogen activator 
inhibitor (PAI-1) is the primary regulator of both t-PA and u- 
PA with dissociation rate constants greater than 10 7 M-1 
s -1 (review [13]). The detection of PAI-1 mRNA and antigen 
associated with human gliomas both in vivo [11,14~18] and in 
vitro [19 23] has led to the concept hat this inhibitor may 
play a role in regulating excessive degradation of the ECM in 
the brain (review [15]). Research in our laboratory and in 
others (reviews [13,24,25]) has revealed that the localized dis- 
tribution of PAI-1 is one mechanism which cells utilize to 
further control the activation of plasminogen and the degra- 
dation of matrix proteins. More specifically, PAI-1 is able to 
bind to vitronectin present in the ECM, which results in the 
localization and stabilization of PAI-1 in the active form 
[13,24,25]. Our group has observed that not only is the secre- 
tion of PAI-I elevated in cultured endothelial cells following 
their treatment with cytokines but an enhanced eposition of 
active PAI-1 both into the ECM and onto the luminal cell 
surface is also observed [26]. Furthermore, PAl-1 is deposited 
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into the storage granules of platelets (i.e. platelet c~-granules) 
in a rapidly releasable form that provides one mechanism to 
control the fibrinolytic system within a local environment in 
the peripheral vasculature (review [27]). Transfection experi- 
ments with expression constructs encoding full length PAI-1 
and a mouse pituitary cell line (i.e. AtT-20 cells) indicated that 
this inhibitor contains a functional domain capable of direct- 
ing it into the regulated secretory pathway [28]. Thus, PAI-1 
contains a number of domains that can regulate its intracel- 
lular and extracellular distribution. Although immunohisto- 
chemical and in situ hybridization analyses of brain tissues 
reveals prominent staining for PAI-1 both in anaplastic ells 
and in areas of necrosis [11,14,16,17], little information cur- 
rently exists on the distribution of PAI-1 associated irectly 
with the gliomas. This study was initiated to investigate this 
issue by utilizing cultured human glioma U-251 cells, an in- 
vasive cell line [10,21] previously observed to contain high 
levels of PAI-1 mRNA [21,29] but no PAI-1 activity in its 
conditioned media [29]. We report that U-251 cells contain 
active PAI-1 stored within intracellular granules in a rapidly 
secretable form. 
2. Materials and methods 
2.1. Analysis of PA and PAl  activities associated with U-251 cells by 
direct and reverse fibrin zymography 
The human glioma U-251 cell line was obtained from Dr. Darrel 
Bigner (Duke University Medical Center, Durham, NC) and cultured 
as described [21]. Media conditioned by U-251 cells for 24 h and cell 
lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) as described previously utilizing a 4% 
stacking gel and a 9% separating el under non-reducing conditions 
[26,28]. The electrophoresed gel was soaked for 1.5 h in 2.5% Triton 
X-100 and subsequently analyzed by either direct or reverse fibrin 
autography as described previously [26,28]. Markers for the gels in- 
cluded Rainbow Coloured Protein Molecular Weight Markers (Amer- 
sham Life Sciences, Arlington Heights, IL), purified urokinase (prod- 
uct no. 124, 80000 IU/mg, mixture of 50 and 33 kDa forms; 
American Diagnostica, Greenwich, CT), purified t-PA (product no. 
111, 700000 IU/mg, 66 kDa, American Diagnostica), and purified 
PAl-1 [28]. Immunodepletion experiments were performed using a 
modification of previously described procedures [30,31]. Briefly, non- 
immune rabbit serum or antiserum to either urokinase [32], t-PA [32], 
PAI-1 [33] (20 ~tl, respectively) were added to protein A-coated Se- 
pharose CL-4B beads (80 lag; Pharmacia, Uppsala, Sweden) that had 
been rehydrated and washed according to the manufacturer's instruc- 
tions. U-251 conditioned media or cell lysates (100 ~tl corresponding 
to 105 cells) were incubated (1 h, 23°C) with the beads. The beads 
were removed by centrifugation and the supernatant fluid analyzed by 
SDS-PAGE and direct or reverse fibrin autography. 
2.2. Immunofluorescence analysis of PAI-I 
Human U-251 cells (10 4 cells/cm 2) were seeded onto fibronectin- 
coated (10 ~tg/cm2; Sigma Chemical Co.) glass coverslips (12 mm 
diameter; Fisher Scientific Co., Pittsburgh, PA) in serum-free med- 
ium. The next day, the cells were fixed with 4% paraformaldehyde (20 
min, 4°C), and PAI-1 antigen localized immunofluorescently utilizing 
previously described protocols [28]. 
2.3. Detection of PAI-1 and amyloid [I-protein precursor (APP) in 
subcellular fractions of U-251 cells 
U-251 cells (10 s cells) were homogenized, and the membrane/organ- 
elle-rich fraction was isolated by differential centrifugation and sub- 
sequently fractionated on 20% Percoll gradients as described pre- 
viously [28]. PAI-I activity was quantitated as previously described 
[26,31] by using immobilized t-PA (American Diagnostica) to bind 
active PAI-1 in a sample and the bound PAI-1 immunologically de- 
tected by incubation with affinity-purified rabbit anti-PAI-1 (10 lag/ml 
[33]) followed by 125I-goat anti-rabbit IgG (50000 cpm/well; Amer- 
sham). PAI-1 antigen was quantitated using a two-site immunoradio- 
metric assay (IRMA) [31] that employed immobilized monoclonal 
antibody against human PAI-1 (clone 2D2; Gibco, Glasgow, UK) 
to bind PAI-1 antigen in a sample and bound PAI-1 detected as 
described above. The distribution of APP in the fractions from the 
Percoll gradient were determined by dot blotting using a modification 
of previously described protocols [28] that employed monoclonal anti- 
body 22Cll anti-APP (1 lag/ml; Boehringer Mannheim, Indianapolis, 
IN) as the primary antibody. 
2.4. Secretagogue treatment of U-251 
U-251 cells (10 6 cells/dish) were plated in 60 mm diameter tissue 
culture dishes and the cells were allowed to equilibrate by incubation 
(37°C, 24 h) in growth media. For experimental nalysis, the cells 
were incubated with two changes of serum-free media over a 2 h 
period, and subsequently incubated for 1 h in serum-free media sup- 
plemented either with or without the secretagogue, 5 mM 8-bromo- 
adenosine 3':5'-cyclic monophosphate (8-Br-cAMP) [28,34,35]. Con- 
ditioned media was collected uring each 1 h period. 
3. Results and discussion 
3.1. Fibrinolytic profile o f  U-251 cells' 
Fractionation of the conditioned media of U-251 cells on 
non-reducing SDS-PAGE followed by fibrin autography re- 
vealed the presence of a single zone of fibrinolysis at 50 kDa 
(Fig. 1A, lane 3). The enzyme responsible for this fibrinolytic 
zone co-migrated with the 50 kDa lytic zone observed utilizing 
a commercially available urokinase preparation (Fig. 1A, lane 
1) and as observed by Sitrin and co-workers [29] using casein- 
zymographic analysis, the enzyme secreted by U-251 cells that 
was responsible for the 50 kDa lytic zone was dependent upon 
the presence of plasminogen (data not shown). A similar 50 
kDa zone of fibrinolysis was detected using U-251 cell lysates 
(Fig. 1A, lane 4). Fig. IB demonstrates the parallel analysis of 
the U-251 samples for PAI activity by SDS-PAGE and re- 
verse fibrin autography. A single lysis-resistant zone was pres- 
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Fig. 1. Fibrinolytic profile of PAs and PAls expressed by U-251 
cells. (A) Samples were subjected to SDS-PAGE and analyzed by fi- 
brin zymography. Lanes: 1, purified urokinase (10 ng); 2, purified 
t-PA standard (10 ng); 3, conditioned medium from U-251 cell cul- 
ture after 24 h incubation under serum-free conditions (100 ~tl corre- 
sponding to the media conditioned by 105 cells); 4, U-251 cell lysate 
(105 cells/lane). (B) Samples were subjected to SDS-PAGE and ana- 
lyzed by reverse fibrin zymography. Lanes: 1, purified PAI-1 (50 
ng); 2, conditioned medium from U-251 cell culture after 24 h incu- 
bation under serum-free conditions (100 ~tl corresponding to the 
media conditioned by 105 cells)); 3, U-251 cell lysate (105 cells/ 
lane). Positions of molecular weight standards are indicated. 
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ent in the media conditioned by the U-251 cells (Fig. 1B, lane 
2), as well as associated with the U-251 cell lysates (Fig. 1B, 
lane 3), and the lysis-resistant zone co-migrated with the ac- 
tivity of purified PAI-1 (Fig. 1 B, lane 1). The inhibitor respon- 
sible for the lysis resistant zone could be immunodepleted 
from both U-251 conditioned media and cell lysates using 
Sepharose anti-PAI-1, whereas the enzyme responsible for 
the 50 kDa lytic zone could be immunodepleted using Sephar- 
ose anti-urokinase but not with Sepharose anti-t-PA (data not 
shown). It should be noted that active PAI-1 released into 
solution is rapidly converted at physiological temperatures 
(T~/2, 1 h) into a latent form whose activity can be detected 
following treatment with denaturants (e.g. SDS-PAGE) [13] 
and thus, the presence of primarily latent PAI-I coupled with 
high levels of u-PA in the conditioned media would account 
for the inability of Sitrin and co-workers [29] to detect PAI-I 
in the U-251 conditioned media. 
3.2. Subcellular distribution o f  PAL1 in U-251 cells 
Immunofluorescence analysis was initially utilized to inves- 
tigate the cellular distribution of this inhibitor. Fig. 2 indicates 
that intense staining for PAI-1 was observed in two distinct 
regions: (i) in the perinuclear egion (Fig. 2A) and (ii) in 
cellular processes (Fig. 2C). Examination of these latter fields 
by phase contrast microscopy suggested that the punctate 
staining of PAI-1 within the cellular processes was localized 
to membrane-bound organelles (data not shown). No specitic 
staining was observed utilizing non-immune IgG as the pri- 
mary antibody (Fig. 2B,D). A similar pattern of staining was 
observed using a commercially available monoclonal antibody 
(no. 380, American Diagnostica) against PAI-1 as the primary 
antibody (data not shown). 
Because the punctate PAI-1 staining pattern in U-251 cells 
was reminiscent of the distribution of PAI-1 in the dense core 
storage granules present within the cellular processes of PAI- 
l-transfected AtT-20 cells [28], we utilized density gradient 
/ 
3 
Fig. 2. Immunofluorescence staining of PAl-1 in human U-251 cells. 
Subconfluent cultures of human U-251 cells were grown overnight 
in serum-free medium, fixed with paraformaldehyde, permeabilized 
with 1% Triton X-100 and incubated with affinity purified rabbit 
anti-PAI-1 (A,C [28]) or with nonimmune rabbit IgG (B,D). Bound 
antibodies were detected by incubation with fluorescein-labelled goat 
anti-rabbit IgG. The samples were examined using an Olympus BH- 
RFL microscope quipped with a DN-100 dichroic mirror, an O- 
515 barrier filter, and a mercury lamp for excitation. Samples were 
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Fig. 3. Subcellular fractionation of U-251 cells. U-251 cells (10 s 
cells) were homogenized and their cellular organelles were centri- 
fuged on a 20% Percoll density gradient. Fractions (800 p.1) were 
collected starting from the top of the gradient. (A) Fractions were 
analyzed for PAI-1 antigen in a two-site IRMA. APP antigen was 
analyzed by dot blotting using anti-APP clone 22C11 as the primary 
antibody followed by ]2'~'I-goat nti-mouse lgG (105 cpm/ml) and 
the radioactivity associated with each dot determined in a gamma- 
counter. (B) Zymographic analysis of u-PA in Percoll gradient sub- 
cellular fractions of U-251 cells: urokinase (lane 1, 10 ng); t-PA 
(lane 2, 10 ng); fractions 3 (lane 3, 100 gl); fraction 9 (lane 4, 100 
~tl); fraction 14 (lane 5, 100 gl). (C) Analysis of PAI-I activity in 
U-251 subcellular fractions utilizing a functional immunoassay. 
fractionation to further characterize the PAI- l -containing 
subcellular organelles of U-251 cells. For this purpose, U- 
251 cells were homogenized, the subcellular organelles were 
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Fig. 4. Secretagogue-induced secretion of PAI-1 from U-251 cells. 
U-251 cells were incubated for two consecutive 1 h time periods un- 
der serum-free conditions and the conditioned media harvested to 
define basal PAI-I secretion. The cells were subsequently incubated 
for 1 h in serum-free media in the absence or presence of 5 mM 8- 
Br-cAMP. The harvested conditioned media were analyzed for PAI- 
l antigen in a two-site IRMA (A) and for PAI-1 activity in a func- 
tional immunoassay (B). 
pelleted by centrifugation, and subjected to ultracentrifuga- 
tion on 20% Percoll. Analysis of PAI-1 in the isolated frac- 
tions revealed that PAI-1 was present in two distinct areas of 
the gradient (Fig. 3A): (i) a low density band that has been 
observed to correspond to rough endoplasmic reticulum, Gol- 
gi apparatus, cellular membranes [34,35] and (ii) a high den- 
sity, storage granule-containing region [34,35]. To demon- 
strate specificity for this fractionation protocol, APP was 
selected because of its distribution within diverse cell subfrac- 
tions. For example, APP has been observed (i) to be stored in 
conjunction with other proteins (e.g. PAI-1) within platelet c~- 
granules, (ii) to undergo fast axonal transport in neurons, and 
(iii) to be endocytosed and proteolytically processed in lyso- 
somes; however, this protein is constitutively secreted in all 
other cell types examined so far including a classical model 
cell system (i.e. AtT-20 cells) for investigating the packaging 
of proteins (e.g. PAI-1 [28]) into the regulated secretory path- 
way [36]. Thus, data on the distribution of APP in the sub- 
factions would provide an insight into the specificity of this 
cell's regulated secretory pathway for PAI-1. Dot blotting 
analysis of APP using a monoclonal antibody against he ex- 
tracellular domain of APP revealed that this protein was pre- 
sent only in the low density region (Fig. 3A). 
Because complexes between u-PA and PAI-1 have been 
observed to be internalized via the lipoprotein-receptor related 
protein into lysosomes [8], we investigated the possibility that 
we were immunologically detecting PAI-1 antigen associated 
with u-PA in endosomes or lysosomes contaminating the high 
density region of the gradient. Firstly, fibrin zymography of 
isolated fractions revealed that u-PA activity could only be 
detected in the low density region (Fig. 3B, lane 3) and was 
absent in the high density region (Fig. 3B, lane 5). Secondly, 
analysis of the activity for PAI-1 in a functional immunologic 
assay revealed that the high density region contained the ma- 
jority of active PAI-1 (Fig. 3C). 
3.3. Secretagogue-induced s cretion of PAL1 Jrom U-251 cells 
The presence of active PAI-1 in the high density regions of 
the Percoll gradient, which have been observed to contain 
dense core secretory granules of AtT-20 cells [34,35], raised 
the possibility that PAI-1 may be present in a rapidly releas- 
able form in U-251 cells. To examine this issue, U-251 cells 
were washed repeatedly over a 2 h period and subsequently 
incubated for 1 h in the presence and absence of 8-Br-cAMP, 
a secretagogue of the regulated secretory pathway [34,35]. Fig. 
4 indicates that the presence of 8-Br-cAMP resulted in a 3- 
fold increase in the PAI-1 antigen (panel A) and activity (pan- 
el B) of the media conditioned by U-251 cells in comparison 
to the media conditioned in the absence of this secretagogue. 
Taken together, our data indicate that U-251 cells contain 
active PAI-1 stored in a rapidly releasable state. The role of 
this form of PAI-I may be related to the wide-spread istri- 
bution of u-PA detected in gliomas in vivo [11,12]. Although 
cell-associated u-PA appears to be required for the migration 
of numerous types of cells [8] including U-251 cells [10], our 
observations coupled with the report of Sitrin and co-workers 
[29] indicate that the secretion of high levels of u-PA from U- 
251 cells results in a net plasminogen activation activity in the 
milieu surrounding these cells. Because u-PA is able to directly 
activate latent collagenase [37], Reith and Rucklidge [37] have 
proposed a cyclic model in which these two enzymes could 
initiate cellular damage, disruption of blood brain barrier, and 
subsequent release of plasminogen from the damaged vessel. 
Thus, high levels of rapidly releasable active PAI-1 might be 
important as a local control mechanism to prevent proteases, 
which are secreted by the tumor cells themselves, from exces- 
sively degrading the surrounding ECM and causing necrosis 
of the tumors. In light of the ability of neuronal cells to 
package and secrete a wide variety of proteins and other mol- 
ecules [38], the derivation of gliomas from neuroectodermal 
cellular lineage [2] raises the possibility that a regulated secre- 
tory pathway may exist in other types of gliomas and hence, 
the packaging of PAI-1 and its role in regulating excessive 
protease activity within the brain may be more complex 
than previously envisioned. 
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